Company intelligence / Profile preview

Tract Pharmaceuticals

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Tract Therapeutics is a clinical-stage biotechnology company developing proprietary personalized cellular therapies aimed at restoring immune balance. The company's lead product candidate, Topotreg, utilizes ex vivo expanded autologous regulatory T cells (Tregs) to prevent organ rejection and treat autoimmune diseases without the need for lifelong toxic immunosuppressants. By leveraging its patented Trisome platform, Tract aims to provide a more natural and durable solution for immune system regulation. The company is currently advancing its lead program through Phase 2 clinical trials in kidney transplant recipients.

Therapeutic areas: ImmunologyNephrology
Modalities: Cell therapyT cell therapyRegulatory T cell therapy
Industry: Biotech

Partnerships

Northwestern University

Beyond the preview

Go deeper on Tract Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tract Pharmaceuticals.

Explore the full profile